125 related articles for article (PubMed ID: 1871935)
1. [Molecular biology studies of bladder cancer].
Bringuier PP; Knopf HJ; Schalken JA; Debruyne FM
Urologe A; 1991 May; 30(3):167-71. PubMed ID: 1871935
[TBL] [Abstract][Full Text] [Related]
2. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
3. Genetic and epigenetic aspects of bladder cancer.
Kim WJ; Quan C
J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
[TBL] [Abstract][Full Text] [Related]
4. [Tumor markers and prognostic parameters in urinary bladder cancer].
Schneider AW; Huland H
Urologe A; 1990 Mar; 29(2):71-6. PubMed ID: 2184571
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic methods in the diagnosis of invasive bladder cancer.
Krause FS; Feil G; Zumbrägel A; Bichler KH
Anticancer Res; 2000; 20(6D):5015-21. PubMed ID: 11326660
[TBL] [Abstract][Full Text] [Related]
6. DNA-aneuploidy as marker for neoplasia in G1-urothelial carcinomas.
Planz B; Striepecke E; Wolff JM; Effert P; Jakse G; Böcking A
Gen Diagn Pathol; 1996 Oct; 142(2):69-73. PubMed ID: 8950570
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers for detection, surveillance and prognostication of bladder cancer.
Vrooman OP; Witjes JA
Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
[TBL] [Abstract][Full Text] [Related]
8. Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer.
Puntoni M; Zanardi S; Branchi D; Bruno S; Curotto A; Varaldo M; Bruzzi P; Decensi A
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):979-83. PubMed ID: 17507625
[TBL] [Abstract][Full Text] [Related]
9. [The molecular biology of bladder carcinoma].
Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
[TBL] [Abstract][Full Text] [Related]
10. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
11. The value of DNA cytometry in transitional cell carcinoma of the urinary bladder.
Nenning H; Rassler J; Minh DH; Stolzenburg JU
Gen Diagn Pathol; 1997 Dec; 143(4):231-6. PubMed ID: 9489956
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic markers in transitional carcinoma of the bladder].
Blasco E; Gutiérrez-Hoyos A; Garrido C; Arozena F
Arch Esp Urol; 1991; 44(1):47-52. PubMed ID: 2064423
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic factors and markers used in urothelial carcinoma of the bladder].
Billerey C; Vieillefond A
Ann Pathol; 1999; 19(5 Suppl):S107-9. PubMed ID: 10599469
[No Abstract] [Full Text] [Related]
14. p63 gene expression study and early bladder carcinogenesis.
Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
[TBL] [Abstract][Full Text] [Related]
15. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
16. [Urothelial cancers. Cytogenetic and molecular biology principles].
Strohmeyer T
Urologe A; 1994 Mar; 33(2):122-7. PubMed ID: 7909968
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of invasive bladder cancers: histological and molecular markers.
Liebert M; Seigne J
Semin Urol Oncol; 1996 May; 14(2):62-72. PubMed ID: 8734733
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer.
Bittard H; Lamy B; Billery C
J Urol; 1996 Jun; 155(6):1887-91. PubMed ID: 8618280
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
20. Recent diagnostic modalities for bladder cancer.
Sheinfeld J; Cordon-Cardo C; Bander NH
Immunol Ser; 1990; 53():485-97. PubMed ID: 2151621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
